Top

Published in:

Open Access 01-12-2012 | Research

Novel cancerization marker, TP53, and its role in distinguishing normal tissue adjacent to cancerous tissue from normal tissue adjacent to benign tissue

Authors: Guo-Yan Liu, Kun-Hong Liu, Yin Li, Chao Pan, Ji-Qin Su, Hong-Feng Liao, Ren-Xiang Yv, Zhao-Hui Li, Li Yuan, Huan-Jing Zhang, Chi-Meng Tzeng, Bing Xiong

Published in: World Journal of Surgical Oncology | Issue 1/2012

Abstract

Background

The histopathological and molecular heterogeneity of normal tissue adjacent to cancerous tissue (NTAC) and normal tissue adjacent to benign tissue (NTAB), and the availability of limited specimens make deciphering the mechanisms of carcinogenesis challenging. Our goal was to identify histogenetic biomarkers that could be reliably used to define a transforming fingerprint using RNA in situ hybridization.

Methods

We evaluated 15 tumor-related RNA in situ hybridization biomarkers using tumor microarray and samples of seven tumor-adjacent normal tissues from 314 patients. Biomarkers were determined using comprehensive statistical methods (significance of support vector machine-based artificial intelligence and area under curve scoring of classification distribution).

Results

TP53 was found to be a most reliable index (P <10^-7; area under curve >87%) for distinguishing NTAC from NTAB, according to the results of a significance panel (BCL10, BECN1, BRCA2, FITH, PTCH11 and TP53).

Conclusions

The genetic alterations in TP53 between NTAC and NTAB may provide new insight into the field of cancerization and tumor transformation.

Available only for authorised users

Braakhuis BJ, Leemans CR, Brakenhoff RH: Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice. J Pathol. 2004, 203: 620-621. 10.1002/path.1549.CrossRefPubMed

Han B, Li S, Song D, Poisson-Paré D, Liu G, Luu-The V, Ouellet J, Li S, Labrie F, Pelletier G: Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol. 2008, 112: 194-200. 10.1016/j.jsbmb.2008.10.004.CrossRefPubMed

Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953, 6: 963-968. 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q.CrossRefPubMed

Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003, 63: 1727-1730.PubMed

Barreto SG, Shukla PJ: Pancreatobiliary malignancies–an appreciation of the "field cancerization theory". Arch Pathol Lab Med. 2009, 133: 850-PubMed

Gazdar AF, Minna JD: Multifocal lung cancers–clonality vs field cancerization and does it matter?. J Natl Cancer Inst. 2009, 101: 541-543. 10.1093/jnci/djp059.PubMedCentralCrossRefPubMed

Heaphy CM, Griffith JK, Bisoffi M: Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat. 2009, 118: 229-239. 10.1007/s10549-009-0504-0.CrossRefPubMed

Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, Harrison RF, Shepherd NA, Novelli MR, Jankowski JA, Wright NA: Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology. 2009, 136: 542-550. 10.1053/j.gastro.2008.10.086.CrossRefPubMed

Nonn L, Ananthanarayanan V, Gann PH: Evidence for field cancerization of the prostate. Prostate. 2009, 69: 1470-1479. 10.1002/pros.20983.PubMedCentralCrossRefPubMed

10.

Schafer M, Werner S: Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008, 9: 628-638. 10.1038/nrm2455.CrossRefPubMed

11.

Wu Y, Zhou BP: New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai). 2008, 40: 643-650. 10.1111/j.1745-7270.2008.00443.x.CrossRef

12.

Guarino M, Rubino B, Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007, 39: 305-318. 10.1080/00313020701329914.CrossRefPubMed

13.

Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J: Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005, 5: 45-10.1186/1471-2407-5-45.PubMedCentralCrossRefPubMed

14.

Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009, 457: 102-106. 10.1038/nature07623.PubMedCentralCrossRefPubMed

15.

Chin L, Gray JW: Translating insights from the cancer genome into clinical practice. Nature. 2008, 452: 553-563. 10.1038/nature06914.PubMedCentralCrossRefPubMed

16.

Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009, 463: 191-196.PubMedCentralCrossRefPubMed

17.

Witz IP: Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res. 2008, 100: 203-229.CrossRefPubMed

18.

Witz IP: Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res. 2008, 68: 9-13. 10.1158/0008-5472.CAN-07-2917.CrossRefPubMed

19.

Weinberg RA: Coevolution in the tumor microenvironment. Nat Genet. 2008, 40: 494-495. 10.1038/ng0508-494.CrossRefPubMed

20.

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR: A census of human cancer genes. Nat Rev Cancer. 2004, 4: 177-183. 10.1038/nrc1299.PubMedCentralCrossRefPubMed

21.

Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature. 2009, 458: 719-724. 10.1038/nature07943.PubMedCentralCrossRefPubMed

22.

Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008, 27: 5904-5912. 10.1038/onc.2008.271.PubMedCentralCrossRefPubMed

23.

Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991, 253: 49-53. 10.1126/science.1905840.CrossRefPubMed

24.

Green DR, Kroemer G: Cytoplasmic functions of the tumour suppressor p53. Nature. 2009, 458: 1127-1130. 10.1038/nature07986.PubMedCentralCrossRefPubMed

25.

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature. 2007, 445: 661-665. 10.1038/nature05541.CrossRefPubMed

26.

Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C: Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci. 2008, 99: 324-332. 10.1111/j.1349-7006.2007.00691.x.CrossRefPubMed

27.

Wang X, Wang M, MacLennan GT, Abdul-Karim FW, Eble JN, Jones TD, Olobatuyi F, Eisenberg R, Cummings OW, Zhang S, Lopez-Beltran A, Montironi R, Zheng S, Lin H, Davidson DD, Cheng L: Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009, 101: 560-570. 10.1093/jnci/djp054.CrossRefPubMed

28.

Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992, 355: 846-847. 10.1038/355846a0.CrossRefPubMed

29.

Kubo Y, Urano Y, Yoshimoto K, Iwahana H, Fukuhara K, Arase S, Itakura M: p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol. 1994, 102: 440-444. 10.1111/1523-1747.ep12373002.CrossRefPubMed

30.

Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 1994, 264: 1317-1319. 10.1126/science.8191284.CrossRefPubMed

Title: Novel cancerization marker, TP53, and its role in distinguishing normal tissue adjacent to cancerous tissue from normal tissue adjacent to benign tissue
Authors: Guo-Yan Liu
Kun-Hong Liu
Yin Li
Chao Pan
Ji-Qin Su
Hong-Feng Liao
Ren-Xiang Yv
Zhao-Hui Li
Li Yuan
Huan-Jing Zhang
Chi-Meng Tzeng
Bing Xiong
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-10-252

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Novel cancerization marker, TP53, and its role in distinguishing normal tissue adjacent to cancerous tissue from normal tissue adjacent to benign tissue

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study

Endoscopically observable white nodule caused by distal intramural lymphatic spread of rectal cancer: a case report

Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder

Surgical properties and survival of a pericardial window via left minithoracotomy for benign and malignant pericardial tamponade in cancer patients

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib